Skip to main content

Advertisement

Table 2 Characteristics of the population (n = 241)

From: Erectile function after permanent 125I prostate brachytherapy for localized prostate cancer

  Mean ± SD (Min-max)
Age (years) 66 ± 7 (43 – 80)
Pre-treatment PSA (ng/mL) 6.6 ± 2.2 (1.2 - 12.6)
Pre-treatment index of prostatic symptom score (IPSS) 4.0 ± 2.8 (0 – 15)
Pre-treatment prostate volume (cm 3 ) 36.3 ± 9.7 (14 – 67)
  N (%)
Gleason score None 10 (4.2)
  < 6 43 (17.8)
  6 146 (60.6)
  7 42 (17.4)
Stage T1C 147 (61)
  T2A 89 (37)
  T2B 5 (2)
Diabetes 19 (8)
Vascular disorders 46 (19)
Obesity (Body mass Index > 2.8) 22 (9)
Contraindication to surgery 25 (10)
Neoadjuvant hormonal therapy* 63 (26)
  1. * LHRH agonists in 10 patients (15.9%), non-steroidal antiandrogens in 6 (9.5%), cyproterone acetate in 25 (39.7%), and complete androgen blockade in 22 (34.9%).